Skip to main content
Top
Published in: Reactions Weekly 1/2011

01-09-2011 | Case report

Etanercept/infliximab

Sarcoidosis: 5 case reports

Published in: Reactions Weekly | Issue 1/2011

Login to get access

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literature
1.
go back to reference Javot L, Tala S, Scala-Bertola J, Massy N, Trenque T, Baldin B, Andrejak M, Gillet P, Petitpain N.Sarcoidosis and anti-TNF: A paradoxical class effect? Analysis of the French pharmacovigilance system database and literature review. Therapie 66: 149-154, No. 2, Mar-Apr 2011. Available from: URL: http://dx.doi.org/10.2515/therapie/2011014 - France Javot L, Tala S, Scala-Bertola J, Massy N, Trenque T, Baldin B, Andrejak M, Gillet P, Petitpain N.Sarcoidosis and anti-TNF: A paradoxical class effect? Analysis of the French pharmacovigilance system database and literature review. Therapie 66: 149-154, No. 2, Mar-Apr 2011. Available from: URL: http://​dx.​doi.​org/​10.​2515/​therapie/​2011014 - France
Metadata
Title
Etanercept/infliximab
Sarcoidosis: 5 case reports
Publication date
01-09-2011
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2011
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201113670-00064

Other articles of this Issue 1/2011

Reactions Weekly 1/2011 Go to the issue

Case report

Infliximab

Case report

Methotrexate